SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Zoé L E van Kempen; Eva M M Strijbis; Marissa M C T Al; Maurice Steenhuis; Bernard M J Uitdehaag; Theo Rispens; Joep Killestein

doi:10.1001/jamaneurol.2021.1364

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

JAMA Neurol. 2021 Jul 1;78(7):880-882. doi: 10.1001/jamaneurol.2021.1364.

Authors

Zoé L E van Kempen¹, Eva M M Strijbis¹, Marissa M C T Al¹, Maurice Steenhuis², Bernard M J Uitdehaag¹, Theo Rispens², Joep Killestein¹

Affiliations

¹ Department of Neurology, Amsterdam Neuroscience, Amsterdam MS Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
² Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands.

Abstract

This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Viral / analysis*
COVID-19 / complications*
COVID-19 / epidemiology
COVID-19 / immunology*
Cohort Studies
Female
Humans
Male
Middle Aged
Multiple Sclerosis / complications
Multiple Sclerosis / epidemiology
Netherlands / epidemiology
Prospective Studies

Substances

Antibodies, Viral